Latest news with #BioTech
Yahoo
a day ago
- Business
- Yahoo
Bio-Techne beats quarterly estimates on strength in protein sciences unit
(Reuters) -Bio-Techne reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research. The Minneapolis, Minnesota-based company develops and makes products used in medical research, drug development and diagnostics. Larger peers Thermo Fisher and Danaher last month flagged robust demand across regions for their drug development products such as instruments and analytical tools after two years of weak biotech funding. Despite ongoing market uncertainty, Bio-Techne reported strong performance in its cell therapy and protein analysis instrumentation units, supported by a resilient pharma market, CEO Kim Kelderman said in a statement. On an adjusted basis, the company posted a profit of 53 cents per share, beating analysts' average estimate of 50 cents, according to data compiled by LSEG data. Revenue was up 3.6% at $316.96 million, ahead of estimates of $315.60 million, driven by its protein sciences unit. The company's largest segment develops and manufactures biological compounds used for research and diagnostics. Late on Tuesday, Bio-Techne said Belgium-based diagnostics firm Mdxhealth SA will buy its Exosome Diagnostics business in an all-stock deal valued at $5 million. The deal will allow the company to increase its focus on high-growth areas, particularly tools for research and precision diagnostics, Kelderman said. The transaction is expected to close in the next quarter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Business
- Yahoo
5 Revealing Analyst Questions From Bio-Techne's Q1 Earnings Call
Bio-Techne's first quarter results were met with a positive market reaction as the company delivered both organic revenue growth and adjusted profit above Wall Street expectations. Management attributed this momentum to robust demand from large pharmaceutical customers, particularly in its core reagents and protein analysis tools, as well as continued execution on cost control and operational efficiency. CEO Kim Kelderman highlighted the company's ability to manage profitability despite an uncertain macro environment, pointing to "strong execution across our product portfolio" and initiatives to drive operational efficiencies. The team noted that these gains were achieved even as the academic research market in the United States faced headwinds related to changes in federal funding policies. Is now the time to buy TECH? Find out in our full research report (it's free). Revenue: $316.2 million vs analyst estimates of $317.4 million (4.2% year-on-year growth, in line) Adjusted EPS: $0.56 vs analyst estimates of $0.51 (10.4% beat) Adjusted EBITDA: $119.1 million vs analyst estimates of $114.1 million (37.7% margin, 4.3% beat) Operating Margin: 12.2%, down from 22.1% in the same quarter last year Organic Revenue rose 5.7% year on year (2.3% in the same quarter last year) Market Capitalization: $8.26 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Puneet Souda (Leerink Partners) asked about the impact of academic funding uncertainty and potential pull-forward in pharma orders. CFO Jim Hippel clarified that pharma growth was sustained, not the result of early demand, and academic headwinds were most pronounced after policy announcements. Dan Leonard (UBS) questioned the company's tariff exposure and manufacturing flexibility. CEO Kim Kelderman explained that regional manufacturing and supply chain adjustments largely insulated Bio-Techne from tariff impacts, especially regarding instruments and consumables exported to China. Matt Larew (William Blair) sought clarity on the sustainability of organic growth rates and margin outperformance. Hippel responded that recent margin improvements were due to disciplined cost controls, and any temporary slowdown from macro headwinds should reverse once uncertainty resolves. Daniel Markowitz (Evercore ISI) asked whether projected academic headwinds would meaningfully impact long-term growth assumptions. Hippel stated that even in severe budget cut scenarios, academic exposure is limited and the company's strategic plan still targets double-digit growth. Patrick Donnelly (Citi) inquired about trends among biotech customers and the performance of the Wilson Wolf joint venture. Kelderman noted that biotech demand was flat, reflecting sensitivity to broader capital markets, while Wilson Wolf continued to deliver solid double-digit growth. Over the next few quarters, our analyst team will be monitoring (1) clarity in NIH funding and U.S. academic research budgets, (2) the pace and effectiveness of tariff mitigation efforts on global operations, and (3) further adoption of new product platforms in organoid solutions and spatial biology. Progress in margin improvement initiatives and the performance of China and biotech customer segments will also be important indicators. Bio-Techne currently trades at $53, up from $47.64 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
National Post
09-06-2025
- Business
- National Post
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Article content BOSTON & SYDNEY — Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. Article content 'The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey,' said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. 'Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry'. Article content BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. Article content The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. Article content BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Article content Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. Article content Article content Article content Article content Article content Article content
